> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Accelerated Approval for Opdivo and Yervoy
- URL: https://www.fdaweb.com/accelerated-approval-for-opdivo-and-yervoy/
- Published: 2020-03-11T12:00:00.000Z
- Updated: 2026-09-14T16:06:41.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146304

FDA has granted accelerated approval to the combination of Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab) for patients with hepatocellular carcinoma who have been previously treated with sorafenib (Bayer’s Nexavar). An FDA [announcement](https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications?ref=fdaweb.com) says the efficacy of the combination was investigated in cohort 4 of the CHECKMATE-040 study in hepatocellular carcinoma patients who progressed on or were intolerant to Nexavar.